1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …

Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …

Background Due to a paucity of data on the efficacy and safety of direct oral anticoagulants
(DOACs) in patients with a body mass index> 40 kg/m 2 or a weight> 120 kg, the use of …

Abstract Background Direct oral anticoagulants (DOACs) do not require concentration
monitoring. However, whether DOAC concentrations are stable and their variation between …

Background Emerging safety and efficacy data for rivaroxaban suggest traditional therapy
and rivaroxaban are comparable in the morbidly obese. However, real‐world data that …

Background Obesity is a global epidemic and bariatric surgery is used with increasing
frequency to treat its complications. The extent to which bariatric surgery alters the efficacy …

Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

Atrial fibrillation (AF) is the most common cardiac arrhythmia. AF increases the risk of stroke,
heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both …

Rivaroxaban has been widely used to prevent and treat various thromboembolic diseases
for more than a decade. However, whether a lower dose of rivaroxaban is required for …